Cambridge Major Laboratories, Inc.
Cambridge Major Laboratories, Inc. (www.c-mlabs.com) is a leading, global chemistry-based contract research organization (“CRO”) providing comprehensive chemistry outsourcing solutions to a diverse customer base of over 150 companies, including some of the world’s largest pharmaceutical, small/mid-sized biotechnology, and generic drug companies. As an end-to-end supplier of high science chemistry services, CML partners with its clients to efficiently and cost effectively advance drugs through the mission critical development and regulatory approval process. CML offers customers a broad array of chemistry services, delivering a complete life cycle of capabilities including process chemistry, solid state chemistry, analytical services, active pharmaceutical ingredients ("API") production services and regulatory services. CML’s comprehensive offering enables the Company to address its customers’ full spectrum of chemistry-based needs from preclinical development to commercialization. The company is headquartered in Germantown, WI.
Arlington made an initial investment in CML in February 2007 and subsequently supported CML’s acquisition of ChemShop B.V. in November 2007. CML is led by its Chief Executive Officer Brian Scanlan, who has been with the Company for more than 10 years, and CFO Mark Abatto, who was formerly the CFO of GE Healthcare US Diagnostic Imaging.
In 2012, Cambridge Major Laboratories, Inc. was sold to publicly traded American Capital, Limited.
(Press Release for Acquisition of ChemShop B.V.)
(Press Release for Investment in CML, Inc.)
(Press Release for sale of Cambridge Major Laboratories, Inc. to American Capital Limited)